Literature DB >> 27778054

[Comment on: Andexanet alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.]

H Lier1, O Grottke2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27778054     DOI： 10.1007/s00101-016-0240-x

Source DB:  PubMed          Journal:  Anaesthesist        ISSN： 0003-2417            Impact factor:   1.041


× No keyword cloud information.
  4 in total

1.  Engineering Reversal - Finding an Antidote for Direct Oral Anticoagulants.

Authors:  Beverley J Hunt; Marcel Levi
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

2.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

Review 3.  [Dealing with massive bleeding and associated perioperative coagulopathy: recommendations for action of the German Society of Anaesthesiology and Intensive Care Medicine].

Authors:  O Grottke; T Frietsch; M Maas; H Lier; R Rossaint
Journal:  Anaesthesist       Date:  2013-03       Impact factor: 1.041

4.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.